Abstract:We have evaluated four hepatitis E virus (HEV) specific antibody assays, using sequential samples taken from 86 rhesus monkeys at intervals for up to 86 weeks after they had been infected with different doses of HEV. The animals are a common experimental model of hepatitis E. The large collection of sequential samples used avoids uncertainties encountered in previous studies regarding the precise infection status of study subjects and minimizes bias due to the individuality of response to infection. One assay (YES IgG) was produced with synthetic peptides; the others (E2 IgM, E2 IgG, and GL IgG) were produced with recombinant antigens. The results were compared with the viral RNA contents of the serum and stool samples and the occurrence of these virological and immunological markers in the course of the infection was temporally related to the development of hepatitis. Diagnostic utility of the markers was assessed according to their response rates and prevalence at different times in the course of infection. All the animals produced E2 IgG and developed viremia and all but one also produced E2 IgM and excreted the virus in stool, whereas response rates for the other antibodies were lower and decreased with virus dose. Hepatitis occurred over a period of 4 weeks between 3 and 7 weeks after infection. Virological activity occurred mainly during the incubation period and the prevalence of viral markers declined rapidly after the onset of hepatitis. Production of the E2 antibodies immediately preceded the onset of hepatitis, and this was followed about one week later by production of the other antibodies. Seroprevalence E2 IgM reached a peak value 3 weeks after the onset of hepatitis, whereas seroprevalence of GL IgG and YES IgG peaked after the disease had subsided. E2 IgG persisted in all animals for the entire duration of the experiment of up to 86 weeks and possibly beyond and, thus, can serve as a useful epidemiological marker of HEV infection. (C) 2003 Wiley-Liss, Inc.

Quantitative Evaluation of Protective Antibody Response Induced by Hepatitis E Vaccine in Humans

Longitudinal Mapping of Hepatitis B Vaccine-Induced B-cell Linear Epitopes in Healthy Individuals

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine

A Phase 1, Double-blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin®) Vaccine in Healthy US Adults

Multi-epitope vaccine design for hepatitis E virus based on protein ORF2 and ORF3

Management Of Hepatitis E Virus (Hev) Zoonotic Transmission: Protection Of Rabbits Against Hev Challenge Following Immunization With Hev 239 Vaccine

Evaluation of antibody-based and nucleic acid-based assays for diagnosis of hepatitis E virus infection in a rhesus monkey model.

A novel multi‐epitope peptide vaccine candidate targeting hepatitis E virus: An in silico approach

Immunization of human hepatitis E viruses conferred protection against challenge by a camel hepatitis E virus

Development and Validation of a New Serum Standard for the Measurement of Anti‐hev Antibodies in Animals

Hepatitis E: an overview and recent advances in vaccine research.

A Preliminary Study on Immune Response to Hepatitis E Virus DNA Vaccine in Mice.

Identification and characterization of two linear epitope motifs in hepatitis E virus ORF2 protein

A Pilot Study on an Attenuated Chinese EIAV Vaccine Inducing Broadly Neutralizing Antibodies

Broadly Reactive Real-Time RT-PCR Assay for the Detection of Hepatitis E Virus and Simultaneous Genotyping by Single Nucleotide Polymorphism Analysis

A multispecies competitive nanobody-based ELISA for the detection of antibodies against hepatitis E virus

Immunobiology and Host Response to HEV.

Design Technique for Enhancing Software Quality and Development Suitability

Evaluation of novel synthetic peptides of avian hepatitis E virus ORF2 as vaccine candidate in chickens

[Blastocystis hominis: epidemiological and clinical remarks from more than 3,500 stool examinations].